<DOC>
	<DOCNO>NCT00244985</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy , liposomal doxorubicin , work different way stop growth cancer cell , either kill cell stop divide . Giving rituximab together liposomal doxorubicin may kill cancer cell . PURPOSE : This phase I/II trial study side effect give rituximab together liposomal doxorubicin see well work treat patient relapsed refractory B-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Rituximab Liposomal Doxorubicin Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety , include qualitative quantitative toxic effect duration reversibility , rituximab doxorubicin HCl liposome patient relapse refractory , indolent aggressive CD20-positive B-cell non-Hodgkin 's lymphoma . Secondary - Determine efficacy , include overall response rate durability objective response , regimen patient . - Correlate pretreatment functional , phenotypic , genotypic characteristic host immune effector cell response patient treat regimen . OUTLINE : This open-label , pilot study . Patients receive rituximab IV 3-8 hour day 1 doxorubicin HCl liposome IV 1-3 hour day 3 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 4 year . PROJECTED ACCRUAL : A total 42 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow indolent aggressive Bcell nonHodgkin 's lymphoma ( NHL ) subtypes : Grade 13 follicular lymphoma Mantle cell lymphoma Small lymphocytic lymphoma Diffuse large Bcell lymphoma Diffuse mix cell lymphoma Marginal zone lymphoma Relapsed refractory CD20positive disease Measurable disease Must receive ≥ 1 &lt; 4 prior standard chemotherapy regimens No Burkitt 's lymphoma precursor Blymphoblastic lymphoma No CNS lymphoma PATIENT CHARACTERISTICS : Performance status Karnofsky 60100 % Life expectancy At least 6 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 75,000/mm^3 Hemoglobin &gt; 7 g/dL Hepatic AST ALT &lt; 2 time upper limit normal ( unless due primary disease ) Bilirubin ≤ 2 mg/dL Renal Creatinine ≤ 2.0 mg/dL Cardiovascular LVEF ≥ 50 % MUGA and/or 2D echocardiogram No history New York Heart Association class IIIV cardiac disease No congestive heart failure Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known HIV positivity No uncontrolled active bacterial , viral , fungal infection No serious disease would preclude study participation No primary malignancy within past 5 year except squamous cell basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy Recovered prior immunotherapy Prior immunotherapy , include rituximab monoclonal antibody , allow Chemotherapy See Disease Characteristics More 4 week since prior chemotherapy recover No prior doxorubicin ( equivalent anthracycline ) cumulative dose &gt; 400 mg/m^2 No concurrent chemotherapy Endocrine therapy Nonsteroidal hormone nonlymphomarelated condition ( e.g. , insulin diabetes ) allow No concurrent corticosteroid except transient inflammatory reaction ( i.e. , skin rash hive ) Radiotherapy Recovered prior radiotherapy No concurrent radiotherapy Surgery More 4 week since prior major surgery ( diagnostic surgery ) recover Other No concurrent antitumor agents No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>